0000000000199436

AUTHOR

Oliver Deuster

showing 4 related works from this author

Efficacy of Short-term Treatment of Internet and Computer Game Addiction

2019

Importance Internet and computer game addiction represent a growing mental health concern, acknowledged by the World Health Organization. Objective To determine whether manualized cognitive behavioral therapy (CBT), using short-term treatment for internet and computer game addiction (STICA), is efficient in individuals experiencing internet and computer game addiction. Design, Setting, and Participants A multicenter randomized clinical trial was conducted in 4 outpatient clinics in Germany and Austria from January 24, 2012, to June 14, 2017, including follow-ups. Blinded measurements were conducted. A consecutive sample of 143 men was randomized to the treatment group (STICA; n = 72) or wai…

AdultMalemedicine.medical_specialtyAdolescentmedia_common.quotation_subjectlaw.inventionYoung Adult03 medical and health sciences0302 clinical medicineRandomized controlled triallawOutcome Assessment Health CareComputer addictionHumansOutpatient clinicMedicinemedia_commonCognitive Behavioral Therapybusiness.industryAddictionRemission Inductionmedicine.disease030227 psychiatryComputer gamePsychiatry and Mental healthInternet addiction disorderVideo GamesPhysical therapyPsychotherapy BriefbusinessAddictive behaviorPsychosocialInternet Addiction Disorder030217 neurology & neurosurgeryFollow-Up StudiesJAMA Psychiatry
researchProduct

Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma:Â a Phase II Trial (GOAL)

2018

Abstract Background: A substantial proportion of patients fail first line treatment of diffuse large B-cell lymphoma. Currently available salvage therapies are often ineffective and cannot be tolerated, especially for elderly patients. Thus, probably less than 25% of patients achieve a long lasting remission. Regimens like gemcitabine/oxaliplatin, or bendamustin, both in combination with rituximab are available for elderly or after failure of HDT, however induce only short lived responses. Obinutuzumab (GA101) is a type II anti-CD20 antibody, with preclinical evidence of superiority over rituximab in xenograft models of MCL and DLBCL. Recently a large phase III trial failed to show a benefi…

Subset AnalysisPediatricsmedicine.medical_specialtyImmunologyMedizinNeutropeniaBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMedian follow-upObinutuzumabClinical endpointMedicinePixantronebusiness.industryCell BiologyHematologymedicine.diseasechemistry030220 oncology & carcinogenesisRituximabbusinessFebrile neutropenia030215 immunologymedicine.drugBlood
researchProduct

The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients Wi…

2021

There is a high need for novel treatment options in relapsed and refractory diffuse large B-cell lymphoma. Single agent mammalian target of rapamycin (mTOR) inhibitor treatment has shown promising efficacy in this entity. Here, we report on the results of the mTOR-inhibitor temsirolimus combined to standard rituximab-DHAP salvage regimen in a prospective, multicenter, phase II, open-label study. The STORM regimen consisted of rituximab 375 mg/m(2) (day 2) and DHAP (dexamethasone 40 mg day 3-6, cisplatinum 100 mg/m(2) day 3, cytarabine 2 × 2  g/m(2) day 4) with temsirolimus added on day 1 and 8 of a 21-day cycle, with 2 to 4 cycles planned. In part I, dose levels of 25, 50, 75, and 100 mg fo…

OncologyCancer Researchmedicine.medical_specialtybusiness.industryHematology002ArticleTemsirolimusddc:TransplantationRegimenRefractoryInternal medicineDHAPmedicineCytarabineDiseases of the blood and blood-forming organsRituximabRC633-647.5businessDexamethasonemedicine.drug
researchProduct

Naturally occurring autoantibodies interfere with β-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer's disease 24 h …

2013

There is evidence that naturally occurring antibodies directed against Aβ (nAbs-Aβ) have a role in Aβ-metabolism and Aβ-clearance. The presence of nAbs-Aβ leads to a reduction in amyloid fibrillation and thus a reduction in their toxicity. We investigated the effects of nAbs-Aβ in respect to oligomerization and used the Tg2576 transgenic mouse model in order to investigate the rapid effect with a single-dose (24 h) on oligomer breakdown and cytokine secretion along with immunohistochemical characterization of synaptic plasticity. nAbs-Aβ were able to reduce toxic oligomer concentration with an increase in Aβ-monomers. Cytokine secretion was significantly reduced. Synaptic plasticity was als…

Genetically modified mousemedicine.medical_specialtytoxic oligomersAmyloidBlotting WesternEnzyme-Linked Immunosorbent AssayMice TransgenicBiologyAnimals Genetically ModifiedCellular and Molecular NeuroscienceMiceCognitionAlzheimer DiseaseInternal medicinemedicineAnimalsBiological PsychiatryAutoantibodiesAmyloid beta-Peptidesβ-amyloidbehaviorAutoantibodyAlzheimer's diseasemedicine.diseasenatural occurring autoantibodiesCell biologyPsychiatry and Mental healthDisease Models AnimalEndocrinologyinflammationSynaptic plasticityToxicitybiology.proteinCytokinesCytokine secretionOriginal ArticleFemaleAlzheimer's diseaseAntibodyTranslational Psychiatry
researchProduct